Latest Insider Transactions at Indaptus Therapeutics, Inc. (INDP)
This section provides a real-time view of insider transactions for Indaptus Therapeutics, Inc. (INDP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Indaptus Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Indaptus Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Jeffrey A Meckler CEO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,553
+17.34%
|
$42,553
$1.18 P/Share
|
|
Aug 08
2024
|
Jeffrey A Meckler CEO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,932
+34.63%
|
$84,932
$1.82 P/Share
|
|
Aug 14
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
23,934
+1.97%
|
$47,868
$2.34 P/Share
|
|
Aug 11
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
35,064
+2.92%
|
$70,128
$2.12 P/Share
|
|
Aug 10
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
44,354
+3.77%
|
$44,354
$1.94 P/Share
|
|
Dec 01
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+30.3%
|
$500
$1.87 P/Share
|
|
Nov 22
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+43.48%
|
$500
$1.83 P/Share
|
|
Nov 21
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
9,600
+11.3%
|
$9,600
$1.9 P/Share
|
|
Nov 18
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
400
+0.6%
|
$400
$1.76 P/Share
|
|
Sep 08
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
10,308
+13.62%
|
$20,616
$2.8 P/Share
|
|
Sep 07
2022
|
Walt Addison Linscott Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
150
+50.0%
|
$300
$2.62 P/Share
|
|
Sep 07
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
8,632
+13.55%
|
$17,264
$2.57 P/Share
|
|
Sep 06
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,060
+2.23%
|
$2,120
$2.44 P/Share
|
|
Jun 06
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
19,727
+30.3%
|
$39,454
$2.63 P/Share
|
|
Mar 02
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
50
+25.0%
|
$200
$4.09 P/Share
|
|
Feb 01
2022
|
Michael James Newman CSO and Director |
SELL
Open market or private sale
|
Indirect |
14,130
-1.02%
|
$70,650
$5.0 P/Share
|
|
Jan 31
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100
+50.0%
|
$400
$4.65 P/Share
|
|
Jan 31
2022
|
Michael James Newman CSO and Director |
SELL
Open market or private sale
|
Indirect |
5,870
-0.42%
|
$29,350
$5.0 P/Share
|
|
Nov 18
2021
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
11,187
+30.37%
|
$55,935
$5.82 P/Share
|
|
Sep 14
2021
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
12,000
+45.35%
|
$84,000
$7.0 P/Share
|